Top

Published in:

Open Access 01-12-2016 | Review

The inflammatory protein Pentraxin 3 in cardiovascular disease

Authors: Francesco Fornai, Albino Carrizzo, Maurizio Forte, Mariateresa Ambrosio, Antonio Damato, Michela Ferrucci, Francesca Biagioni, Carla Busceti, Annibale A. Puca, Carmine Vecchione

Published in: Immunity & Ageing | Issue 1/2016

Abstract

The acute phase protein Pentraxin 3 (PTX3) plays a non-redundant role as a soluble pattern recognition receptor for selected pathogens and it represents a rapid biomarker for primary local activation of innate immunity and inflammation. Recent evidence indicates that PTX3 exerts an important role in modulating the cardiovascular system in humans and experimental models. In particular, there are conflicting points concerning the effects of PTX3 in cardiovascular diseases (CVD) since several observations indicate a cardiovascular protective effect of PTX3 while others speculate that the increased plasma levels of PTX3 in subjects with CVD correlate with disease severity and with poor prognosis in elderly patients.

In the present review, we discuss the multifaceted effects of PTX3 on the cardiovascular system focusing on its involvement in atherosclerosis, endothelial function, hypertension, myocardial infarction and angiogenesis. This may help to explain how the specific modulation of PTX3 such as the use of different dosing, time, and target organs could help to contain different vascular diseases. These opposite actions of PTX3 will be emphasized concerning the modulation of cardiovascular system where potential therapeutic implications of PTX3 in humans are discussed.

Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005;23:337–66. doi:10.1146/annurev.immunol.23.021704.115756.CrossRefPubMed

Gewurz H, Zhang XH, Lint TF. Structure and function of the pentraxins. Curr Opin Immunol. 1995;7:54–64. doi:10.1016/0952-7915(95)80029-8.CrossRefPubMed

Mantovani A, Garlanda C, Doni A, Bottazzi B. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol. 2008;28:1–13. doi:10.1007/s10875-007-9126-7.CrossRefPubMed

Bonacina F, Barbieri SS, Cutuli L, Amadio P, Doni A, Sironi M, et al. Vascular pentraxin 3 controls arterial thrombosis by targeting collagen and fibrinogen induced platelets aggregation. Biochim Biophys Acta. 2016. doi:10.1016/j.bbadis.2016.03.007.PubMedPubMedCentral

Bottazzi B, Inforzato A, Messa M, Barbagallo M, Magrini E, Garlanda C, et al. The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling. J Hepatol. 2016. doi:10.1016/j.jhep.2016.02.029.PubMed

Agrawal A, Singh PP, Bottazzi B, Garlanda C, Mantovani A. Pattern recognition by pentraxins. Adv Exp Med Biol. 2009;653:98–116.CrossRefPubMedPubMedCentral

Fornai F, Carrizzo A, Ferrucci M, Damato A, Biagioni F, Gaglione A, et al. Brain diseases and tumorigenesis: the good and bad cops of pentraxin3. Int J Biochem Cell Biol. 2015;69:70–4. doi:10.1016/j.biocel.2015.10.017.CrossRefPubMed

Dubin R, Li YM, Ix JH, Shlipak M, Whooley M, Peralta CA. Associations of Pentraxin-3 with cardiovascular events, incident heart failure and mortality among persons with coronary heart disease: data from the heart and soul study. Circulation. 2011;124.

Introna M, Alles VV, Castellano M, Picardi G, DeGioia L, Bottazzi B, et al. Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites. Blood. 1996;87:1862–72.PubMed

10.

Fuster V, Mearns BM. The CVD paradox: mortality vs prevalence. Nat Rev Cardiol. 2009;6:669. doi:10.1038/nrcardio.2009.187.CrossRefPubMed

11.

Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004;109:II2–10. doi:10.1161/01.CIR.0000129535.04194.38.CrossRefPubMed

12.

Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2004;110:2349–54. doi:10.1161/01.CIR.0000145167.30987.2E.CrossRefPubMed

13.

Inoue K, Kodama T, Daida H. Pentraxin 3: a novel biomarker for inflammatory cardiovascular disease. Int J Vasc Med. 2012;2012:657025. doi:10.1155/2012/657025.PubMedPubMedCentral

14.

Yano Y, Matsuda S, Hatakeyama K, Sato Y, Imamura T, Shimada K, et al. Plasma Pentraxin 3, but not high-sensitivity C-reactive protein, is a useful inflammatory biomarker for predicting cognitive impairment in elderly hypertensive patients. J Gerontol A Biol Sci Med Sci. 2010;65:547–52. doi:10.1093/gerona/glq030.CrossRefPubMed

15.

Norata GD, Garlanda C, Catapano AL. The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc Med. 2010;20:35–40. doi:10.1016/j.tcm.2010.03.005.CrossRefPubMed

16.

Parlak A, Aydogan U, Iyisoy A, Dikililer MA, Kut A, Cakir E, et al. Elevated pentraxin-3 levels are related to blood pressure levels in hypertensive patients: an observational study. Anadolu Kardiyol Derg. 2012;12:298–304. doi:10.5152/akd.2012.092.PubMed

17.

Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–74. doi:10.1038/nature01323.CrossRefPubMed

18.

Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ J. 2010;74:213–20.CrossRefPubMed

19.

Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2002;22:e10–14.CrossRefPubMed

20.

Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein and all-cause mortality--the Copenhagen City Heart Study. Eur Heart J. 2010;31:1624–32. doi:10.1093/eurheartj/ehq103.CrossRefPubMed

21.

Klouche M, Peri G, Knabbe C, Eckstein HH, Schmid FX, Schmitz G, et al. Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis. 2004;175:221–8. doi:10.1016/j.atherosclerosis.2004.03.020.CrossRefPubMed

22.

Savchenko A, Imamura M, Ohashi R, Jiang S, Kawasaki T, Hasegawa G, et al. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol. 2008;215:48–55. doi:10.1002/path.2314.CrossRefPubMed

23.

Mantovani A, Garlanda C, Bottazzi B. Pentraxin 3, a non-redundant soluble pattern recognition receptor involved in innate immunity. Vaccine. 2003;21 Suppl 2:S43–47.CrossRefPubMed

24.

Nerkiz P, Doganer YC, Aydogan U, Akbulut H, Parlak A, Aydogdu A, et al. Serum pentraxin-3 level in patients who underwent coronary angiography and relationship with coronary atherosclerosis. Med Princ Pract. 2015;24:369–75. doi:10.1159/000381879.CrossRefPubMed

25.

Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM. Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 2009;29:594–9. doi:10.1161/ATVBAHA.108.178947.CrossRefPubMedPubMedCentral

26.

Eggers KM, Armstrong PW, Califf RM, Johnston N, Simoons ML, Venge P, et al. Clinical and prognostic implications of circulating pentraxin 3 levels in non ST-elevation acute coronary syndrome. Clin Biochem. 2013;46:1655–9. doi:10.1016/j.clinbiochem.2013.08.014.CrossRefPubMed

27.

Soeki T, Niki T, Kusunose K, Bando S, Hirata Y, Tomita N, et al. Elevated concentrations of pentraxin 3 are associated with coronary plaque vulnerability. J Cardiol. 2011;58:151–7. doi:10.1016/j.jjcc.2011.04.005.CrossRefPubMed

28.

Kotooka N, Inoue T, Aoki S, Anan M, Komoda H, Node K. Prognostic value of pentraxin 3 in patients with chronic heart failure. Int J Cardiol. 2008;130:19–22. doi:10.1016/j.ijcard.2007.07.168.CrossRefPubMed

29.

Deban L, Russo RC, Sironi M, Moalli F, Scanziani M, Zambelli V, et al. Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol. 2010;11:328–34. doi:10.1038/ni.1854.CrossRefPubMed

30.

Norata GD, Marchesi P, Pulakazhi Venu VK, Pasqualini F, Anselmo A, Moalli F, et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation. 2009;120:699–708. doi:10.1161/CIRCULATIONAHA.108.806547.CrossRefPubMed

31.

Shindo A, Tanemura H, Yata K, Hamada K, Shibata M, Umeda Y, et al. Inflammatory biomarkers in atherosclerosis: pentraxin 3 can become a novel marker of plaque vulnerability. PLoS One. 2014;9:e100045. doi:10.1371/journal.pone.0100045.CrossRefPubMedPubMedCentral

32.

Napoleone E, di Santo A, Peri G, Mantovani A, de Gaetano G, Donati MB, et al. The long pentraxin PTX3 up-regulates tissue factor in activated monocytes: another link between inflammation and clotting activation. J Leukoc Biol. 2004;76:203–9. doi:10.1189/jlb.1003528.CrossRefPubMed

33.

Bassi N, Zampieri S, Ghirardello A, Tonon M, Zen M, Cozzi F, et al. Pentraxins, anti-pentraxin antibodies, and atherosclerosis. Clin Rev Allergy Immunol. 2009;37:36–43. doi:10.1007/s12016-008-8098-6.CrossRefPubMed

34.

Qiu L, Xu R, Wang S, Li S, Sheng H, Wu J, et al. Honokiol ameliorates endothelial dysfunction through suppression of PTX3 expression, a key mediator of IKK/IkappaB/NF-kappaB, in atherosclerotic cell model. Exp Mol Med. 2015;47:e171. doi:10.1038/emm.2015.37.CrossRefPubMedPubMedCentral

35.

Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. 2006;113:1708–14. doi:10.1161/CIRCULATIONAHA.105.602532.CrossRefPubMed

36.

Puca AA, Carrizzo A, Ferrario A, Villa F, Vecchione C. Endothelial nitric oxide synthase, vascular integrity and human exceptional longevity. Immun Ageing. 2012;9:26. doi:10.1186/1742-4933-9-26.CrossRefPubMedPubMedCentral

37.

Carnevale D, Pallante F, Fardella V, Fardella S, Iacobucci R, Federici M, et al. The angiogenic factor PlGF mediates a neuroimmune interaction in the spleen to allow the onset of hypertension. Immunity. 2014;41:737–52. doi:10.1016/j.immuni.2014.11.002.CrossRefPubMed

38.

Clapp BR, Hingorani AD, Kharbanda RK, Mohamed-Ali V, Stephens JW, Vallance P, et al. Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress. Cardiovasc Res. 2004;64:172–8. doi:10.1016/j.cardiores.2004.06.020.CrossRefPubMed

39.

Witasp A, Ryden M, Carrero JJ, Qureshi AR, Nordfors L, Naslund E, et al. Elevated circulating levels and tissue expression of pentraxin 3 in uremia: a reflection of endothelial dysfunction. PLoS One. 2013;8:e63493. doi:10.1371/journal.pone.0063493.CrossRefPubMedPubMedCentral

40.

Hamad RR, Eriksson MJ, Berg E, Larsson A, Bremme K. Impaired endothelial function and elevated levels of pentraxin 3 in early-onset preeclampsia. Acta Obstet Gynecol Scand. 2012;91:50–6. doi:10.1111/j.1600-0412.2011.01238.x.CrossRefPubMed

41.

Cozzi V, Garlanda C, Nebuloni M, Maina V, Martinelli A, Calabrese S, et al. PTX3 as a potential endothelial dysfunction biomarker for severity of preeclampsia and IUGR. Placenta. 2012;33:1039–44. doi:10.1016/j.placenta.2012.09.009.CrossRefPubMed

42.

Suliman ME, Qureshi AR, Carrero JJ, Barany P, Yilmaz MI, Snaedal-Jonsdottir S, et al. The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortality. QJM. 2008;101:397–405. doi:10.1093/qjmed/hcn019.CrossRefPubMed

43.

Jylhava J, Haarala A, Kahonen M, Lehtimaki T, Jula A, Moilanen L, et al. Pentraxin 3 (PTX3) is associated with cardiovascular risk factors: the Health 2000 Survey. Clin Exp Immunol. 2011;164:211–7. doi:10.1111/j.1365-2249.2011.04354.x.CrossRefPubMedPubMedCentral

44.

Tamura Y, Ono T, Kuwana M, Inoue K, Takei M, Yamamoto T, et al. Human pentraxin 3 (PTX3) as a novel biomarker for the diagnosis of pulmonary arterial hypertension. PLoS One. 2012;7:e45834. doi:10.1371/journal.pone.0045834.CrossRefPubMedPubMedCentral

45.

Naito A, Tanabe N, Jujo T, Shigeta A, Sugiura T, Sakao S, et al. Pentraxin3 in chronic thromboembolic pulmonary hypertension: a new biomarker for screening from remitted pulmonary thromboembolism. PLoS One. 2014;9:e113086. doi:10.1371/journal.pone.0113086.CrossRefPubMedPubMedCentral

46.

Souza DG, Amaral FA, Fagundes CT, Coelho FM, Arantes RM, Sousa LP, et al. The long pentraxin PTX3 is crucial for tissue inflammation after intestinal ischemia and reperfusion in mice. Am J Pathol. 2009;174:1309–18. doi:10.2353/ajpath.2009.080240.CrossRefPubMedPubMedCentral

47.

Carrizzo A, Lenzi P, Procaccini C, Damato A, Biagioni F, Ambrosio M, et al. Pentraxin 3 induces vascular endothelial dysfunction through a P-selectin/Matrix metalloproteinase-1 pathway. Circulation. 2015;131:1495–505. doi:10.1161/CIRCULATIONAHA.114.014822. discussion 1505.CrossRefPubMed

48.

Okrainec K, Banerjee DK, Eisenberg MJ. Coronary artery disease in the developing world. Am Heart J. 2004;148:7–15. doi:10.1016/j.ahj.2003.11.027.CrossRefPubMed

49.

Haibo Liu, Xiaofang Guo, Kang Yao, Chunming Wang, Guozhong Chen, Wei Gao, Jie Yuan, Wangjun Yu, Junbo Ge. Pentraxin-3 Predicts Long-Term Cardiac Events in Patients with Chronic Heart Failure. BioMedResearch International. 2015;1-7.

50.

Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F, et al. PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation. 2000;102:636–41.CrossRefPubMed

51.

Duran S, Duran I, Kaptanagasi FA, Nartop F, Ciftci H, Korkmaz GG. The role of pentraxin 3 as diagnostic value in classification of patients with heart failure. Clin Biochem. 2013;46:983–7. doi:10.1016/j.clinbiochem.2013.04.026.CrossRefPubMed

52.

Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T, et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J. 2008;155:75–81. doi:10.1016/j.ahj.2007.08.013.CrossRefPubMed

53.

Matsubara J, Sugiyama S, Nozaki T, Sugamura K, Konishi M, Ohba K, et al. Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J Am Coll Cardiol. 2011;57:861–9. doi:10.1016/j.jacc.2010.10.018.CrossRefPubMed

54.

Latini R, Gullestad L, Masson S, Nymo SH, Ueland T, Cuccovillo I, et al. Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials. Eur J Heart Fail. 2012;14:992–9. doi:10.1093/eurjhf/hfs092.CrossRefPubMed

55.

Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Mukai S, et al. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol. 2007;27:161–7. doi:10.1161/01.ATV.0000252126.48375.d5.CrossRefPubMed

56.

Helseth R, Solheim S, Opstad T, Hoffmann P, Arnesen H, Seljeflot I. The time profile of Pentraxin 3 in patients with acute ST-elevation myocardial infarction and stable angina pectoris undergoing percutaneous coronary intervention. Mediators Inflamm. 2014;2014:608414. doi:10.1155/2014/608414.CrossRefPubMedPubMedCentral

57.

Matsui S, Ishii J, Kitagawa F, Kuno A, Hattori K, Ishikawa M, et al. Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis. 2010;210:220–5. doi:10.1016/j.atherosclerosis.2009.10.033.CrossRefPubMed

58.

Haibo L, Xiaofang G, Chunming W, Jie Y, Guozhong C, Limei Z, et al. Prognostic value of plasma pentraxin-3 levels in patients with stable coronary artery disease after drug-eluting stent implantation. Mediators Inflamm. 2014;2014:963096. doi:10.1155/2014/963096.CrossRefPubMedPubMedCentral

59.

Salio M, Chimenti S, De Angelis N, Molla F, Maina V, Nebuloni M, et al. Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2008;117:1055–64. doi:10.1161/CIRCULATIONAHA.107.749234.CrossRefPubMed

60.

Salustri A, Garlanda C, Hirsch E, De Acetis M, Maccagno A, Bottazzi B, et al. PTX3 plays a key role in the organization of the cumulus oophorus extracellular matrix and in in vivo fertilization. Development. 2004;131:1577–86. doi:10.1242/dev.01056.CrossRefPubMed

61.

Day AJ, de la Motte CA. Hyaluronan cross-linking: a protective mechanism in inflammation? Trends Immunol. 2005;26:637–43. doi:10.1016/j.it.2005.09.009.CrossRefPubMed

62.

Presta M, Oreste P, Zoppetti G, Belleri M, Tanghetti E, Leali D, et al. Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists. Arterioscler Thromb Vasc Biol. 2005;25:71–6. doi:10.1161/01.ATV.0000148863.24445.b4.PubMed

63.

Camozzi M, Zacchigna S, Rusnati M, Coltrini D, Ramirez-Correa G, Bottazzi B, et al. Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo. Arterioscler Thromb Vasc Biol. 2005;25:1837–42. doi:10.1161/01.ATV.0000177807.54959.7d.CrossRefPubMed

64.

Leali D, Inforzato A, Ronca R, Bianchi R, Belleri M, Coltrini D, et al. Long pentraxin 3/tumor necrosis factor-stimulated gene-6 interaction: a biological rheostat for fibroblast growth factor 2-mediated angiogenesis. Arterioscler Thromb Vasc Biol. 2012;32:696–703. doi:10.1161/ATVBAHA.111.243998.CrossRefPubMedPubMedCentral

65.

Rodriguez-Grande B, Varghese L, Molina-Holgado F, Rajkovic O, Garlanda C, Denes A, et al. Pentraxin 3 mediates neurogenesis and angiogenesis after cerebral ischaemia. J Neuroinflammation. 2015;12:15. doi:10.1186/s12974-014-0227-y.CrossRefPubMedPubMedCentral

66.

Woo JM, Kwon MY, Shin DY, Kang YH, Hwang N, Chung SW. Human retinal pigment epithelial cells express the long pentraxin PTX3. Mol Vis. 2013;19:303–10.PubMedPubMedCentral

67.

Yang HS, Woo JE, Lee SJ, Park SH, Woo JM. Elevated plasma pentraxin 3 levels are associated with development and progression of diabetic retinopathy in Korean patients with type 2 diabetes mellitus. Invest Ophthalmol Vis Sci. 2014;55:5989–97. doi:10.1167/iovs.14-14864.CrossRefPubMed

68.

Zhou W, Hu W. Serum and vitreous pentraxin 3 concentrations in patients with diabetic retinopathy. Genet Test Mol Biomarkers. 2016;20:149–53. doi:10.1089/gtmb.2015.0238.CrossRefPubMed

69.

Min JK, Kim J, Woo JM. Elevated plasma pentraxin3 levels and its association with neovascular age-related macular degeneration. Ocul Immunol Inflamm. 2015;23:205–11. doi:10.3109/09273948.2014.891755.CrossRefPubMed

70.

Park KS, Kim JW, An JH, Woo JM. Elevated plasma pentraxin 3 and its association with retinal vein occlusion. Korean J Ophthalmol. 2014;28:460–5. doi:10.3341/kjo.2014.28.6.460.CrossRefPubMedPubMedCentral

71.

Alberti L, Gilardini L, Zulian A, Micheletto G, Peri G, Doni A, et al. Expression of long pentraxin PTX3 in human adipose tissue and its relation with cardiovascular risk factors. Atherosclerosis. 2009;202:455–60. doi:10.1016/j.atherosclerosis.2008.05.015.CrossRefPubMed

72.

Ogihara Y, Ogata S, Nomoto K, Ebato T, Sato K, Kokubo K, et al. Transcriptional regulation by infliximab therapy in Kawasaki disease patients with immunoglobulin resistance. Pediatr Res. 2014;76:287–93. doi:10.1038/pr.2014.92.CrossRefPubMed

73.

Chick HE, Nowrouzi A, Fronza R, McDonald RA, Kane NM, Alba R, et al. Integrase-deficient lentiviral vectors mediate efficient gene transfer to human vascular smooth muscle cells with minimal genotoxic risk. Hum Gene Ther. 2012;23:1247–57. doi:10.1089/hum.2012.042.CrossRefPubMedPubMedCentral

74.

Acevedo L, Yu J, Erdjument-Bromage H, Miao RQ, Kim JE, Fulton D, et al. A new role for Nogo as a regulator of vascular remodeling. Nat Med. 2004;10:382–8. doi:10.1038/nm1020.CrossRefPubMed

75.

Satomura K, Torigoshi T, Koga T, Maeda Y, Izumi Y, Jiuchi Y, et al. Serum amyloid A (SAA) induces pentraxin 3 (PTX3) production in rheumatoid synoviocytes. Mod Rheumatol. 2013;23:28–35. doi:10.1007/s10165-012-0630-0.CrossRefPubMed

76.

Preda MB, Ronningen T, Burlacu A, Simionescu M, Moskaug JO, Valen G. Remote transplantation of mesenchymal stem cells protects the heart against ischemia-reperfusion injury. Stem Cells. 2014;32:2123–34. doi:10.1002/stem.1687.CrossRefPubMed

77.

Rodriguez-Grande B, Swana M, Nguyen L, Englezou P, Maysami S, Allan SM, et al. The acute-phase protein PTX3 is an essential mediator of glial scar formation and resolution of brain edema after ischemic injury. J Cereb Blood Flow Metab. 2014;34:480–8. doi:10.1038/jcbfm.2013.224.CrossRefPubMed

78.

Merchant S, Korbelik M. Upregulation of genes for C-reactive protein and related pentraxin/complement proteins in photodynamic therapy-treated human tumor cells: enrolment of PI3K/Akt and AP-1. Immunobiology. 2013;218:869–74. doi:10.1016/j.imbio.2012.10.010.CrossRefPubMed

79.

Norata GD, Marchesi P, Pirillo A, Uboldi P, Chiesa G, Maina V, et al. Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol. 2008;28:925–31. doi:10.1161/ATVBAHA.107.160606.CrossRefPubMed

80.

Moalli F, Doni A, Deban L, Zelante T, Zagarella S, Bottazzi B, et al. Role of complement and Fc{gamma} receptors in the protective activity of the long pentraxin PTX3 against Aspergillus fumigatus. Blood. 2010;116:5170–80. doi:10.1182/blood-2009-12-258376.CrossRefPubMed

81.

Juel HB, Faber C, Munthe-Fog L, Bastrup-Birk S, Reese-Petersen AL, Falk MK, et al. Systemic and ocular long pentraxin 3 in patients with age-related macular degeneration. PLoS One. 2015;10:e0132800. doi:10.1371/journal.pone.0132800.CrossRefPubMedPubMedCentral

Title: The inflammatory protein Pentraxin 3 in cardiovascular disease
Authors: Francesco Fornai
Albino Carrizzo
Maurizio Forte
Mariateresa Ambrosio
Antonio Damato
Michela Ferrucci
Francesca Biagioni
Carla Busceti
Annibale A. Puca
Carmine Vecchione
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: Immunity & Ageing / Issue 1/2016
Electronic ISSN: 1742-4933
DOI: https://doi.org/10.1186/s12979-016-0080-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2016

Frailty has a stronger association with inflammation than age in older veterans

HCV monoinfection and HIV/HCV coinfection enhance T-cell immune senescence in injecting drug users early during infection

Nutrigerontology: a key for achieving successful ageing and longevity

The prognostic value of biomarkers in stroke

Dietary phytochemicals and neuro-inflammaging: from mechanistic insights to translational challenges

Nutraceutical effects of table green olives: a pilot study with Nocellara del Belice olives

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials